Tweet
Zogenix, Inc. (NASDAQ:ZGNX) major shareholder Life Sciences Maste Perceptive acquired 100,000 shares of the company's stock in a transaction that occurred on Friday, August 10th. The shares were acquired at an average cost of $52.00 per share, for a total transaction of $5,200,000.00. The acquisition was disclosed in a filing with the SEC, which is available through this link . Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.
Zogenix stock opened at $48.05 on Friday. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -11.95 and a beta of 2.13. Zogenix, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $62.75. Get Zogenix alerts:
Zogenix (NASDAQ:ZGNX) last posted its earnings results on Monday, August 6th. The company reported ($0.82) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.88) by $0.06. During the same period last year, the business posted ($0.90) earnings per share. equities research analysts forecast that Zogenix, Inc. will post -3.72 EPS for the current fiscal year. Institutional investors have recently bought and sold shares of the business. BlueMountain Capital Management LLC acquired a new stake in Zogenix in the second quarter valued at $104,000. SG Americas Securities LLC purchased a new stake in shares of Zogenix in the first quarter valued at $100,000. Meadow Creek Investment Management LLC purchased a new stake in shares of Zogenix in the first quarter valued at $192,000. Amalgamated Bank purchased a new stake in shares of Zogenix in the second quarter valued at $232,000. Finally, Quantitative Systematic Strategies LLC purchased a new stake in shares of Zogenix in the second quarter valued at $239,000.
ZGNX has been the topic of several research reports. Stifel Nicolaus upped their target price on Zogenix from $55.00 to $65.00 and gave the company a "buy" rating in a report on Friday, July 13th. Zacks Investment Research lowered Zogenix from a "hold" rating to a "sell" rating in a report on Thursday, June 21st. Empire upped their target price on Zogenix from $57.00 to $66.00 and gave the company a "buy" rating in a report on Tuesday, July 31st. BidaskClub lowered Zogenix from a "buy" rating to a "hold" rating in a report on Friday, August 10th. Finally, ValuEngine raised Zogenix from a "buy" rating to a "strong-buy" rating in a report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of "Buy" and an average price target of $60.67.
About Zogenix
Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome